Medical Innovation Prize Act of 2007

A bill to provide incentives for investment in research and development for new medicines, to enhance access to new medicines, and for other purposes.

10/19/2007--Introduced.
Medical Innovation Prize Act of 2007 - Prohibits any person from having the right to exclusively manufacture, distribute, sell, or use in interstate commerce a drug, a biological product, or a drug or biological product manufacturing process, including the exclusive right to rely on health registration data or the 30-month stay-of-effectiveness period for Orange Book patents under the Federal Food, Drug, and Cosmetic Act, notwithstanding provisions of that Act and other specified laws. Establishes the Fund for Medical Innovation Prizes. Requires the Board of Trustees for the Fund to award prize payments for medical innovations relating to a drug, biological product, or manufacturing process. Requires an eligible award recipient to be either the first person to receive market clearance or the holder of the patent. Directs the Board to consider:
(1) the number of patients who benefited from the drug, including non-U.S. patients;
(2) the incremental therapeutic benefit of the drug to treat the same disease or condition, except that the Board shall provide for cases where drugs, biological products, or manufacturing processes are developed at roughly the same time so that the comparison is to products that were not recently developed;
(3) the degree to which the drug addresses priority health care needs, such as global infectious diseases and neglected diseases that primarily afflict the poor in developing countries; and
(4) the improved efficiency of manufacturing processes for drugs or biological processes. Allows the Board to award prize payments for no more than ten years. Allocates certain minimum payments from the Fund for priority research and development.
Requires the Comptroller General to conduct an audit to determine the Board's effectiveness in bringing to market new drugs, vaccines, biological products, and manufacturing processes in a cost-effective manner and in addressing society's global medical needs.


... morehide bill summarySee Full Bill Text

Sponsor

• Sen. Bernard Sanders [I, VT]

Committees

• Senate Health, Education, Labor, and Pensions

Amendments

This bill has no amendments.

Amendments to S.2210

Number	Status	Purpose

Bill Status

Make a Bill Status Widget

	OpenCongress widgets allow you to display information about bills and issue areas on your own website or blog. First, select which bill or issue you want to track, then customize the appearance of the panel, and finally paste a simple chunk of HTML into your site. Now your community will have an easy, up-to-date way to track the status of important bills and issues in Congress.

Introduced		Voted on by Senate		Voted on by House		Considered By President		Bill Becomes Law
October 19, 2007

Show All Actions (2 actions)Hide Actions

All Bill Actions

• Oct 19, 2007: Read twice and referred to the Committee on Health, Education, Labor, and Pensions.
• Introduced on Oct 19, 2007.

---

Related Issue Areas:

• Vaccines
• Science policy
• Revolving funds
• Research and development
• 20 more
• Pharmaceutical research
• Patents
• Orphan drugs
• Medical innovations
• Medical care
• Marketing
• Intellectual property
• Finance
• Drug industry
• Drug approvals
• Cost effectiveness
• Congressional investigations
• Congress
• Communicable diseases
• Commemorations
• Business
• Budgets
• Awards, medals, prizes
• Auditing
• Medicine

Data from the Congressional Research Service

Users tracking S.2210 (1) are also tracking:

Show More User Statistics... Hide User Statistics

In the News

We are not currently finding any news articles on this topic using our daily automated search of Google News. However, if you know of a relevant news article to display here, OpenCongress site editors have the ability to add it manually. Simply e-mail us the web address of this page and the web address of your suggested news article: We'll post relevant links as quickly as possible. Also, if this topic is important to you, you could write a letter to the editor -- if a news article refers this specific topic by name, a link to that news article is likely to appear here soon.

Information made available by:

Blog Coverage

June 24, 2008 John McCain’s Prize System: $300 Million for Battery Power

Now Pending S.2210 is the "Medical Innovation Prize Act of 2007." The act would attempt to "de-couple" the reward for pharmaceutical product research from the market price of the product. Unlike more traditional prizes, this one would .

Was this article useful? Yes or No

Source: Patent Law Blog (Patently-O)

Did you find this article useful? Your opinion counts - together, we're finding the very best news and blog coverage about Congress available on the web.

April 20, 2008 James Love: University patent managers versus developing countries

A number of experts agree with this approach, which is also set forth in S.2210, the Medical Innovation Prize Fund. The debate in the WHO is actually much more limited. For example, Barbados and Bolivia recently proposed five different ...

Was this article useful? Yes or No

Source: The Full Feed from HuffingtonPost.com

Did you find this article useful? Your opinion counts - together, we're finding the very best news and blog coverage about Congress available on the web.

April 19, 2008 Thomson corp

A number of experts agree with this approach, which is also set forth in S.2210, the Medical Innovation Prize Fund. The debate in the WHO is actually much more limited. For example, Barbados and Bolivia recently proposed five different ...

Was this article useful? Yes or No

Source: Swords in the Angel

Did you find this article useful? Your opinion counts - together, we're finding the very best news and blog coverage about Congress available on the web.

7 more posts...
See most useful blog posts

Information made available by: